LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・Nektar Therapeutics

Nektar Therapeutics

Closed

1.14 1.79

Buy Sell

Overview

Share price change

24h

Current

Min

1.14

Max

1.17

Key metrics
By Trading Economics
Income	-46M
Sales	-259K 24M
EPS	-0.22
Profit margin	-189.848
Employees	137
EBITDA	-32M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+78.57 upside

Dividends
By Dow Jones
Next Earnings	5 Nov 2024

Market Stats
By TradingEconomics
Market Cap	-20M 230M
Previous open	-0.65
Previous close	1.14

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.12 / 1.24 Support & Resistance

Nektar Therapeutics Chart

Related News

6 Sept 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6 Sept 2024, 21:18 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 Sept 2024, 21:05 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 Sept 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 Sept 2024, 20:39 UTC

Earnings

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 Sept 2024, 20:35 UTC

Top News

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 Sept 2024, 20:34 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 Sept 2024, 20:11 UTC

Top News

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 Sept 2024, 19:51 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 Sept 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 Sept 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 Sept 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6 Sept 2024, 18:27 UTC

Top News

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 Sept 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 Sept 2024, 18:15 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 Sept 2024, 18:12 UTC

Top News

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 Sept 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 Sept 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 Sept 2024, 17:30 UTC

Top News

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 Sept 2024, 17:27 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 Sept 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 Sept 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6 Sept 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 Sept 2024, 16:35 UTC

Earnings

Hot Stocks

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 Sept 2024, 16:33 UTC

Acquisitions, Mergers, Takeovers

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 Sept 2024, 16:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

6 Sept 2024, 16:20 UTC

Earnings

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 Sept 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 Sept 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 Sept 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Peer Comparison

Price change

Nektar Therapeutics Forecast

Price Target

By TipRanks

78.57% upside

12 Months Forecast

Average 2 USD 78.57%

High 2 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Nektar Therapeutics - Dist in the past 3 months.

Technical Score

By Trading Central

1.12 / 1.24Support & Resistance

Recent bearish events outweigh bullish events.

There is one bullish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.